Skip to content

Section archive

Parp

Drug

PARP blockers effective in treating hard-to-treat breast cancers

At the ASCO meeting, a study of 116 triple negative breast cancer patients found those given a PARP inhibitor with chemotherapy lived 3.5 months longer than those on chemotherapy alone. An AstraZeneca PARP inhibitor shrank tumors in 41 percent of BRCA mutation carriers.

2 min read

1 story